Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Tongzhen Xu, Lingling Feng, Wenjue Zhang, Haoyue Li, Huiying Ma, Muyasha Abulimiti, Yutong Tan, Feiyan Deng, Wenting Huang, Shuangmei Zou, Wenyan Kang, Liming Jiang, Ying Wang, Chen Hu, Yinggang Chen, Haitao Zhou, Yuan Tang, Jing Jin
BACKGROUND: For patients with locally advanced rectal cancer (LARC), total neoadjuvant therapy (TNT), namely, intensifying preoperative treatment through the integration of radiotherapy and systemic chemotherapy before surgery, was commonly recommended as the standard treatment. However, the risk of distant metastasis at 3 years remained higher than 20%, and the complete response (CR) rate was less than 30%. Several clinical trials had suggested a higher complete response rate when combining single-agent immunotherapy with short-course radiotherapy (SCRT)...
April 19, 2024: BMC Cancer
#22
JOURNAL ARTICLE
Dong Xing, Yongbin Lv, Bolin Sun, Tongpeng Chu, Qianhao Bao, Han Zhang
RATIONALE AND OBJECTIVES: To develop and validate a nomogram that combines contrast-enhanced spectral mammography (CESM) deep learning with clinical-pathological features to predict neoadjuvant chemotherapy (NAC) response (either low Miller Payne (MP-L) grades 1-2 or high MP (MP-H) grades 3-5) in patients with ER-positive/HER2-negative breast cancer. MATERIALS AND METHODS: In this retrospective study, 265 breast cancer patients were randomly allocated into training and test sets (used for models training and testing, respectively) at a 4:1 ratio...
April 18, 2024: Academic Radiology
#23
JOURNAL ARTICLE
Chisato Narita, Fumihiko Urabe, Wataru Fukuokaya, Kosuke Iwatani, Yu Imai, Keiji Yasue, Keiichiro Mori, Koichi Aikawa, Takafumi Yanagisawa, Shoji Kimura, Kojiro Tashiro, Shunsuke Tsuzuki, Yuta Yamada, Steffi Kar Kei Yuen, Jeremy Yuen-Chun Teoh, Tatsuya Shimomura, Hiroki Yamada, Akira Furuta, Jun Miki, Takahiro Kimura
BACKGROUND: The CheckMate274 trial has reported enhanced disease-free survival rates in patients with stage pT3-4/ypT2-4 or pN+ urothelial carcinoma (UC) undergoing adjuvant nivolumab therapy. This study compares prognostic differences between urothelial carcinoma of the bladder (UCB) and upper tract urothelial carcinoma (UTUC). METHODS: We retrospectively analyzed data from 719 patients with UC who underwent radical surgery, stratifying to patients at stage pT3-4 and/or pN+ without neoadjuvant chemotherapy (NAC) or at ypT2-4 and/or ypN+ with NAC (potential candidates for adjuvant immunotherapy), and to those who were not candidates for adjuvant immunotherapy...
March 21, 2024: Clinical Genitourinary Cancer
#24
JOURNAL ARTICLE
J W Awori Hayanga, Xun Luo, Islam Hasasna, Paul Rothenberg, Shalini Reddy, J Hunter Mehaffey, Jason Lamb, Vinay Badhwar, Alper Toker
BACKGROUND: Race is a potent influencer of healthcare access. Geography and income may exert equal or greater influence on patient outcomes. We sought to define the intersection of race, rurality, and income and their influence on access to minimally invasive lung surgery in Medicare beneficiaries. METHODS: Medicare and Medicaid Services data were used to evaluate patients with lung cancer who underwent right upper lobectomy, via open, robotic-assisted (RATS), or video-assisted thoracic surgery (VATS) between 2018 and 2020...
April 17, 2024: Annals of Thoracic Surgery
#25
JOURNAL ARTICLE
Manish S Bhandare, Kaival K Gundavda, Raghav Yelamanchi, Amit Chopde, Swati Batra, Manjushree Kolhe, Anant Ramaswamy, Vikas Ostwal, Kedar Deodhar, Vikram Chaudhari, Shailesh V Shrikhande
BACKGROUND: Advances in perioperative chemotherapy have improved outcomes in patients with gastric cancers (GC). This strategy leads to tumour downstaging and may result in a pathologic complete response (pCR). The study aimed to evaluate the predictors of pCR and determine the impact of pCR on long-term survival. METHODS: At the Department of Gastrointestinal and HPB Oncology at the Tata Memorial Centre, Mumbai, 1001 consecutive patients with locally advanced GCs undergoing radical resection following neoadjuvant chemotherapy from January 2005 to June 2022 were included...
April 16, 2024: European Journal of Surgical Oncology
#26
JOURNAL ARTICLE
Lin Zhao, Ye Wang, Zhenggang Guo
BACKGROUND: While survival rates among cardiac allograft recipients have improved, there has been a rise in post-transplant malignancies, with gastric cancer being less commonly reported. This study presented a successful treatment of gastric cancer in an individual 10 years after undergoing a heart transplant. CASE PRESENTATION: A 66-year-old Chinese man presented to the gastrointestinal clinic with a complaint of diagnosis of gastric cancer for 4 months and treated with neoadjuvant therapy for 1 month...
April 19, 2024: Medicine (Baltimore)
#27
JOURNAL ARTICLE
Áine Higgins, Seamus O'Reilly, Martin J O'Sullivan
BACKGROUND: The coronavirus-19 (COVID-19) pandemic caused delays in the diagnosis and management of breast cancer which may have affected disease presentation. The aim of this study was to compare rates of metastatic disease, tumour characteristics and management in breast cancer patients diagnosed before and after the onset of COVID-19. METHODS: A retrospective chart review was conducted on patients in a university teaching hospital who were diagnosed with invasive symptomatic breast cancer in 2019 (prepandemic control group) and in 2020, 2021, and 2022 (pandemic study groups)...
April 19, 2024: Irish Journal of Medical Science
#28
JOURNAL ARTICLE
Yan Liang, Jing Liu, Jia Ge, Qiyun Shi, Guozhi Zhang, Andi Wan, Tao Luo, Hao Tian, Linjun Fan, Shushu Wang, Li Chen, Peng Tang, Kai Zhu, Jun Jiang, Xiuwu Bian, Yi Zhang, Xiaowei Qi
BACKGROUND: Anlotinib is a new type of tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1/2/3, platelet-derived growth factor receptors α/β, and fibroblast growth factor receptors 1-4 and c-Kit, with a broad spectrum of inhibitory effects on tumor angiogenesis and growth. It has been proven effective in HER2-negative metastatic breast cancer, but its efficacy in early-stage triple-negative breast cancer (TNBC) is unknown. This phase 2 study aims to evaluate the efficacy and safety of adding anlotinib to neoadjuvant chemotherapy in patients with TNBC...
May 2024: EClinicalMedicine
#29
JOURNAL ARTICLE
Mina Sarofim, Ruwanthi Wijayawardana, Nima Ahmadi, Shoma Barat, Winston Liauw, David L Morris
BACKGROUND: Colorectal peritoneal metastases (CRPM) affects 15% of patients at initial colorectal cancer diagnosis. Neoadjuvant chemotherapy (NAC) prior to cytoreductive surgery (CRS) has been demonstrated to be a safe and feasible option, however there is limited data describing its efficacy in advanced peritoneal disease. This study evaluated the effect of NAC on survival in patients with high volume CRPM undergoing CRS with or without HIPEC. METHODS: A retrospective review of all patients who underwent CRS with or without HIPEC for CRPM from 2004 to 2019 at our institution was performed...
April 18, 2024: World Journal of Surgical Oncology
#30
JOURNAL ARTICLE
M C Liefaard, A van der Voort, M van Seijen, B Thijssen, J Sanders, S Vonk, L Mittempergher, R Bhaskaran, L de Munck, A E van Leeuwen-Stok, R Salgado, H M Horlings, E H Lips, G S Sonke
Tumor-infiltrating lymphocytes (TILs) have been associated with outcomes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy and trastuzumab. However, it remains unclear if TILs could be a prognostic and/or predictive biomarker in the context of dual HER2-targeting treatment. In this study, we evaluated the association between TILs and pathological response (pCR) and invasive-disease free survival (IDFS) in 389 patients with stage II-III HER2 positive breast cancer who received neoadjuvant anthracycline-containing or anthracycline-free chemotherapy combined with trastuzumab and pertuzumab in the TRAIN-2 trial...
April 18, 2024: NPJ Breast Cancer
#31
JOURNAL ARTICLE
Wael Mohamed Safwat Sadek, Ibrahim Khairy Fayed Elshamly, Moustafa Saladin Mohammed Salem, Wessam Gamal AbouSenna, Emad Ebeid, Walid Atef Ebeid
BACKGROUND: Osteosarcoma is the most common primary bone malignancy in skeletally immature patients. The proximal humerus is the third most common site of osteosarcoma. The literature shows a paucity of published data concerning the outcome of proximal humerus osteosarcoma managed by limb salvage. The purpose of this study was to answer the following questions: (1) do patients with proximal humerus osteosarcoma managed by limb salvage and neoadjuvant chemotherapy show good functional and oncological outcomes, and (2) are there any prognostic factors that are associated with better oncological and functional outcomes? MATERIALS AND METHODS: The study was a retrospective case series study assessing the overall outcome of 34 patients with proximal humerus osteosarcoma...
April 18, 2024: Journal of Orthopaedics and Traumatology: Official Journal of the Italian Society of Orthopaedics and Traumatology
#32
REVIEW
Christopher Grant, Misako Nagasaka
Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with EGFR and ALK alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with EGFR-TKI monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials' potential benefits, challenges, and future directions in the field...
March 27, 2024: Cancer Treatment Reviews
#33
JOURNAL ARTICLE
Wouter H Zwart, Sofieke J D Temmink, Geke A P Hospers, Corrie A M Marijnen, Hein Putter, Iris D Nagtegaal, Lennart Blomqvist, Elma Meershoek-Klein Kranenbarg, Annet G H Roodvoets, Anna Martling, Cornelis J H van de Velde, Bengt Glimelius, Koen C M J Peeters, Boudewijn van Etten, Per J Nilsson
BACKGROUND: A pathological complete response (pCR) following chemoradiation (CRT) or short-course radiotherapy (scRT) leads to a favourable prognosis in patients with rectal cancer. Total neo-adjuvant therapy (TNT) doubles the pCR rate, but it is unknown whether oncological outcomes remain favourable and whether the same characteristics are associated with pCR as after CRT. METHODS: Comparison between patients with pCR in the RAPIDO trial in the experimental [EXP] (scRT, chemotherapy, surgery, as TNT) and standard-of-care treatment [STD] (CRT, surgery, postoperative chemotherapy depending on hospital policy) groups...
April 7, 2024: European Journal of Cancer
#34
JOURNAL ARTICLE
Anbang Wang, Ming Chen, Duocai Li, Jiazi Shi, Wenbin Tang, Zongqin Zhang, Shancheng Ren
PURPOSE: To evaluate the efficacy and safety of a novel humanized anti-HER2 antibody, RC48-ADC (Disitamab vedotin, DV), the combination of RC48-ADC with PD-1 inhibitors was used to treat muscle-invasive bladder cancer (MIBC). This combination therapy has potential applications in both bladder preservation and neoadjuvant therapy for MIBC. METHODS: Patients with MIBC underwent transurethral resection of bladder tumors followed by RC48-ADC alone or in combination with PD-1 inhibitors...
March 26, 2024: Clinical Genitourinary Cancer
#35
JOURNAL ARTICLE
Jenna Bhimani, Kelli O'Connell, Isaac J Ergas, Marilyn Foley, Grace B Gallagher, Jennifer J Griggs, Narre Heon, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H Kroenke, Cecile A Laurent, Raymond Liu, Kanichi G Nakata, Sonia Persaud, Donna R Rivera, Janise M Roh, Sara Tabatabai, Emily Valice, Erin J A Bowles, Elisa V Bandera, Lawrence H Kushi, Elizabeth D Kantor
PURPOSE: Identification of patients' intended chemotherapy regimens is critical to most research questions conducted in the real-world setting of cancer care. Yet, these data are not routinely available in electronic health records (EHRs) at the specificity required to address these questions. We developed a methodology to identify patients' intended regimens from EHR data in the Optimal Breast Cancer Chemotherapy Dosing (OBCD) study. METHODS: In women older than 18 years, diagnosed with primary stage I-IIIA breast cancer at Kaiser Permanente Northern California (2006-2019), we categorized participants into 24 drug combinations described in National Comprehensive Cancer Network guidelines for breast cancer treatment...
April 2024: JCO Clinical Cancer Informatics
#36
JOURNAL ARTICLE
Yuichiro Miki, Satoshi Nishi, Tatsuro Tamura, Takumi Imai, Mikio Nambara, Tatsunari Fukuoka, Mami Yoshii, Takahiro Toyokawa, Shigeru Lee, Hisako Fujii, Hisako Yoshida, Mitsuhiko Ikebuchi, Kiyoshi Maeda
BACKGROUND: Subtotal esophagectomy with lymph node dissection followed by neoadjuvant chemotherapy (NAC) is the standard treatment for stage II-III esophageal cancer. Esophagectomy is still associated with high morbidity rates, and reducing these rates remains challenging. Among several complications, postoperative pneumonia (PP) is sometimes fatal, which has been reportedly caused by sarcopenia. Thus, nutritional support and rehabilitation may be promising for preventing skeletal muscle mass loss and reduce the incidence of PP...
2024: PloS One
#37
JOURNAL ARTICLE
Hironobu Goto, Taro Oshikiri, Takashi Kato, Yoshiaki Nagatani, Yohei Funakoshi, Yasufumi Koterazawa, Ryuichiro Sawada, Hitoshi Harada, Naoki Urakawa, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Takeru Matsuda, Hironobu Minami, Yoshihiro Kakeji
BACKGROUND: In Japan, preoperative adjuvant chemotherapy followed by surgical resection is the standard treatment for patients with locally advanced esophageal squamous cell carcinoma. However, the risk of recurrence after surgical resection remains high. Although a randomized controlled trial evaluating the efficacy of nivolumab, a fully human monoclonal anti-programmed death 1 antibody, as postoperative adjuvant therapy after neoadjuvant chemoradiotherapy and surgery established its superior efficacy as adjuvant therapy, the efficacy for patients who received preoperative adjuvant chemotherapy has not been demonstrated...
2024: PloS One
#38
JOURNAL ARTICLE
Sergi Fernandez-Gonzalez, Catalina Falo, Maria J Pla, Miriam Campos, Carlos Ortega-Exposito, Raul Ortega, Maria Vicente, Ana Petit, Jan Bosch-Schips, Maria Teresa Bajen, Gabriel Reyes, Evelyn Martínez, Javier González-Viguera, Judith Peñafiel, Agostina Stradella, Sonia Pernas, Jordi Ponce, Amparo Garcia-Tejedor
PURPOSE: In patients with clinically lymph node-negative (cN0) breast cancer, performing sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) has been preferentially embraced in comparison to before NACT. However, survival outcomes associated with both strategies remain understudied. We aimed to compare the axillary lymphadenectomy (ALND) rate, disease-free survival (DFS), and overall survival (OS), between two strategies. METHODS: We included 310 patients in a retrospective observational study...
April 18, 2024: Breast Cancer Research and Treatment
#39
JOURNAL ARTICLE
Francesco Massari, Matteo Santoni, Hideki Takeshita, Yohei Okada, Jose Carlos Tapia, Umberto Basso, Marco Maruzzo, Sarah Scagliarini, Thomas Büttner, Giuseppe Fornarini, Zin W Myint, Luca Galli, Vinicius Carrera Souza, Renate Pichler, Ugo De Giorgi, Nathalia Gandur, Elaine T Lam, Danielle Gilbert, Lazar Popovic, Enrique Grande, Giulia Mammone, Rossana Berardi, Simon J Crabb, Robert Kemp, Javier Molina-Cerrillo, Marcelo Freitas, Murilo Luz, Roberto Iacovelli, Fabio Calabrò, Deniz Tural, Francesco Atzori, Zsófia Küronya, Rita Chiari, Saul Campos, Orazio Caffo, André P Fay, Jakub Kucharz, Paolo Andrea Zucali, José Augusto Rinck, Annalisa Zeppellini, Diogo Assed Bastos, Gaetano Aurilio, Augusto Mota, Karine Trindade, Cinzia Ortega, Juan Pablo Sade, Mimma Rizzo, Ondřej Fiala, Nuno Vau, Patrizia Giannatempo, Allan Barillas, Fernando Sabino M Monteiro, Breno Dauster, Alessia Mennitto, Lucas Nogueira, Roni de Carvalho Fernandes, Emmanuel Seront, Luís Garcia Aceituno, Francesco Grillone, Hernan Javier Cutuli, Mauricio Fernandez, Maria Bassanelli, Ray Manneh Kopp, Giandomenico Roviello, Halima Abahssain, Giuseppe Procopio, Michele Milella, Jindrich Kopecky, Angelo Martignetti, Carlo Messina, Manuel Caitano, Eva Inman, Ravindran Kanesvaran, Daniel Herchhorn, Daniele Santini, Aristotelis Bamias, Renato Bisonni, Alessandra Mosca, Franco Morelli, Fernando Maluf, Andrey Soares, Fernando Nunes, Alvaro Pinto, Anca Zgura, Lorena Incorvaia, Jawaher Ansari, Ignacio Ortego Zabalza, Johannes Landmesser, Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, Matteo Rosellini, Giulia Sorgentoni, Nicola Battelli, Sebastiano Buti, Camillo Porta, Joaquim Bellmunt
BACKGROUND: Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. PATIENTS AND METHODS: Medical records of patients with documented metastatic UC treated by pembrolizumab as second-line therapy were retrospectively collected from 88 institutions in 23 countries...
April 18, 2024: Cancer Immunology, Immunotherapy: CII
#40
JOURNAL ARTICLE
María de Armas Conde, Carmen Díaz-López, Vanessa Concepción-Martín, María Del Pilar Borque-Barrera
BACKGROUND AND STUDY AIMS: Upper gastrointestinal tract (UGT) leaks are associated with severe morbidity and mortality. Endoluminal vacuum (EVAC) therapy is a promising approach for repairing effectively these defects. Our study describes the results obtained from a series of cases treated with EVAC for the management of esophageal anastomotic (EA) leak following esophagectomy for cancer, gastroenteric (GE) anastomoses leak after bariatric surgery and esophageal perforation (EP). PATIENTS AND METHODS: We retrospectively analyzed ten patients who had an EA and GE anastomoses leaks and EP treated with EVAC...
April 18, 2024: Revista Española de Enfermedades Digestivas
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
